CALT
40
-0.16 (-0.4%)
- · NASDAQ
- Sector -
- Industry -
- Website calliditas.se
- Employees(FY) 174
- ISIN -
Performance
-
1W
-
1M
-
3M
+3.12%
6M
-
YTD
+71.75%
1Y
Profile
Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.
Technical Analysis of CALT 2024-09-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-09-16 09:46
- 2024-09-15 21:46
- 2024-09-03 07:13
- 2024-09-03 06:33
- 2024-09-02 19:13
- 2024-09-02 18:33
- 2024-08-14 06:33
3 Swedish Growth Companies With Up To 30% Insider Ownership(Simply Wall St.)
- 2024-08-13 01:25
Calliditas Interim Report January to June 2024(PR Newswire)
- 2024-08-12 13:25
Calliditas Interim Report January to June 2024(Prnewswire)
- 2024-08-05 01:26
- 2024-08-04 13:26
- 2024-08-01 09:00
- 2024-07-31 21:00
- 2024-07-31 08:23
- 2024-07-30 20:23
- 2024-07-26 11:23
- 2024-07-26 02:29
- 2024-07-25 23:23
- 2024-07-25 14:29
- 2024-07-04 03:44
- 2024-07-03 15:44
- 2024-06-18 06:25
Calliditas provides setanaxib patent update(PR Newswire)
- 2024-06-17 18:25
Calliditas provides setanaxib patent update(Prnewswire)
- 2024-06-17 12:01
- 2024-06-17 00:01
- 2024-05-30 22:03
- 2024-05-30 14:20
- 2024-05-30 02:20
- 2024-05-29 06:33
- 2024-05-28 22:04
Page 1 of 7
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.